Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records reported in 2023 — page 3

55 records with a recorded report or completion year of 2023.

Showing 0 records on this page

Records

55 documents · page 3 of 3

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SURMOUNT-2-HEPATIC-IMPprogramme recordTirzepatidePhase 1ReportedPhase 1 ascending dose2023Very low
SURMOUNT-2-PKprogramme recordTirzepatidePhase 1ReportedPhase 1 ascending dose2023Very low
SURMOUNT-2-RENAL-IMPprogramme recordTirzepatidePhase 1ReportedPhase 1 ascending dose2023Very low
SURMOUNT-3TirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled8062023High
SURMOUNT-3-BODY-COMPprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled2023Very low
SURMOUNT-3-QOLprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled2023Very low
SURMOUNT-3-REGIONAL-JPprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled2023Very low

page 3 of 3

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.